Stock Market Watch

Depomed, Inc. announced top-line results from BREEZE 3

by ·



DepoMed, Inc. (NASDAQ:DEPO). Last Market Price: 4.77, Change: -1.51, % Change: (-24.04%). Shares trade in the range of 4.45 – 4.97 dollars. It has a market capitalization of 264.08M dollars, making it a Small Cap Stock and has 55.36M outstanding shares. The company has a beta of 1.62, indicating, the stock to be more volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is 1.73; P/E of 2.75. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 69%. The company has a 52 week high of $ 10.40 and a 52 week low of $ 4.45. Average volumes of shares traded daily are 705,462. Volume traded in the last session was at 2,290,000, 3.25 times the average volume.

  • DepoMed – Press Release
    • Depomed Announces Top-Line Results From Serada(R) Phase 3 Trial BREEZE 3 in Menopausal Hot Flashes
    • Depomed, Inc. announced top-line results from BREEZE 3, a Phase 3 trial evaluating the efficacy and safety of Serada(R) (extended-release gabapentin tablets) for menopausal hot flashes. Serada is a proprietary formulation of gabapentin using patented polymer technology that enables gradual release of the drug.

For Q2 (Jun ’11), It had a Net profit margin of -26.77%, an Operating margin of -28.26%. Other Key stats and ratios are : Return on average assets of -12.56%, Return on average equity of -18.17%. The organization has an employee strength of 69

Consensus Recommendation is a Buy.


Estimate for sales for the Quarter Ending Dec-11 show a mean of 14.31 million dollars, an estimate high of 16.27 million dollars and an estimate low of 12.35 million dollars. A year ago the figures stood at 27.06 million dollars.

Estimate for sales for the Quarter Ending Mar-12 show a mean of 13.36 million dollars, an estimate high of 13.36 million dollars and an estimate low of 13.36 million dollars.

Estimate for EPS for the Quarter Ending Dec-11 show a mean of -0.25 dollars, an estimate high of -0.23 dollars and an estimate low of -0.28 dollars. A year ago the figures stood at 0.06 dollars.

Estimate for EPS for the Quarter Ending Mar-12 show a mean of -0.22 dollars, an estimate high of -0.22 dollars and an estimate low of -0.22 dollars.

Sales for Quarter Ending Jun-11 was estimated at 22.12 million dollars, however the actual sales figure stood at 21.22 million dollars, 0.91 million dollars less than estimates.

Sales for Quarter Ending Mar-11 was estimated at 113.06 million dollars, however the actual sales figure stood at 83.10 million dollars, 29.95 million dollars less than estimates.

edliston
Post Written By: Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.


Tags:

Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...